Gilead Sciences (GILD) Q1 2025 10-Q Quarterly Report
Filed: May 7, 2025Period ending Mar 31, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Gilead Sciences (GILD) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 7, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Gilead Sciences Q1 2025 10-Q Analysis
Risk Factors
- • New regulatory risk: FDA boxed warning on CAR T therapies for secondary T-cell malignancies effective January 2024
- • Updated product commercialization risk: Phase 3 EVOKE-01 trial failed in January 2024, causing impairment charge impacting pipeline valuation
Gilead Sciences Q1 2025 Quarterly FinancialsXBRL
Revenue
$6.7B
▼ -0.3% YoY
Net Income
$1.3B
▲ +131.5% YoY
Operating Margin
33.6%
▲ +9820bp YoY
Net Margin
19.7%
▲ +8209bp YoY
EPS (Diluted)
$1.04
▲ +131.1% YoY
Operating Cash Flow
$1.8B
▼ -20.8% YoY
Source: XBRL data from Gilead Sciences Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Gilead Sciences Quarterly Reports
Get deeper insights on Gilead Sciences
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.